SCHEMBL5810064

SCHEMBL5810064

CCN(CC)CCOc1ccc(C(=O)c2ccccc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EBP Q15125 3/20 0.68
SIGMAR1 Q99720 3/20 0.68
KMT2A Q03164 3/20 0.68
CYP2D6 P10635 3/20 0.68
MAPT P10636 3/20 0.68
KCNH2 Q12809 2/20 0.68
ESR1 P03372 2/20 0.68
CHRM2 P08172 2/20 0.68
ADRA2A P08913 2/20 0.68
ADORA3 P0DMS8 2/20 0.68
CHRM1 P11229 2/20 0.68
PTGS1 P23219 2/20 0.68
SLC6A2 P23975 2/20 0.68
SLC6A4 P31645 2/20 0.68
DRD3 P35462 2/20 0.68
HTR6 P50406 2/20 0.68
SLC6A3 Q01959 2/20 0.68
HTT P42858 2/20 0.68
KDM4E B2RXH2 2/20 0.68
MEN1 O00255 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13305510 0.93 BCHE (0.77) EBPSIGMAR1KMT2ACYP2D6MAPT
SCHEMBL16561567 0.92 KMT2A (0.59) EBPSIGMAR1KMT2ACYP2D6MAPT
SCHEMBL16561513 0.92 GAA (0.64) EBPSIGMAR1KMT2ACYP2D6MAPT
SCHEMBL8770563 0.91 BCHE (0.76) EBPSIGMAR1KMT2ACYP2D6MAPT
SCHEMBL1470323 0.90 PPARA (0.62) EBPSIGMAR1KMT2ACYP2D6MAPT
SCHEMBL9360240 0.90 BCHE (0.78) BCHEACHEGAAPPARA
SCHEMBL12748212 0.86 BCHE (0.55) EBPSIGMAR1KMT2ACYP2D6MAPT
SCHEMBL250102 0.86 EBP (0.69) EBPSIGMAR1KMT2ACYP2D6MAPT
SCHEMBL10882164 0.85 GAA (0.59) EBPSIGMAR1KMT2ACYP2D6MAPT
SCHEMBL10885006 0.85 EBP (0.55) EBPSIGMAR1KMT2ACYP2D6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578025-B2 Processes for the preparation of zuclomiphene intermediates APOTEX INC. (CA) 2023-02-14 US disclosed
US-20220119331-A1 Processes for the Preparation of Zuclomiphene Intermediates THE BANK OF NOVA SCOTIA (CA) 2022-04-21 US disclosed
US-11046638-B2 Processes for the preparation of zuclomiphene and intermediates thereof APOTEX INC. (CA) 2021-06-29 US disclosed
US-20210147337-A1 Processes for the Preparation of Zuclomiphene and Intermediates Thereof THE BANK OF NOVA SCOTIA (CA) 2021-05-20 US disclosed
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-06-24 US disclosed
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-06-24 US disclosed
WO-2006108204-A1 PHOTOPOLYMERISABLE MIXTURES COMPRISING PHOTOINITIATORS BASED ON BENZOPHENONE AND PHENYLGLYCINE TECHNISCHE UNIVERSITÄT WIEN (AT) 2006-10-19 WO disclosed
US-4094908-A Alpha-substituted benzhydrol derivatives RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1978-06-13 US disclosed
US-4082813-A 3-Ioda-α-ethynyl benzhydrol RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1978-04-04 US disclosed
US-4066709-A α-Ethyny benzhydrols RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1978-01-03 US disclosed
US-4039589-A LIVER MICROSOMAL ENZYMES RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1977-08-02 US disclosed
US-3965179-A BLOCKING, VIRICIDE, FUNGICIDE RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1976-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578025-B2 Processes for the preparation of zuclomiphene intermediates CYP4F2, CYP4F12, CYP1A2 EBP 409/4885SIGMAR1 4558/4885KMT2A 275/4885
US-11046638-B2 Processes for the preparation of zuclomiphene and intermediates thereof CYP3A43, UGT1A3, ZDHHC7 EBP 576/4885SIGMAR1 4764/4885KMT2A 897/4885
US-20210147337-A1 Processes for the Preparation of Zuclomiphene and Intermediates Thereof CYP3A43, UGT1A3, ZDHHC7 EBP 576/4885SIGMAR1 4764/4885KMT2A 897/4885
US-20220119331-A1 Processes for the Preparation of Zuclomiphene Intermediates CYP4F2, CYP4F12, CYP1A2 EBP 409/4885SIGMAR1 4558/4885KMT2A 275/4885
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION RCOR3, BRD3, BRPF3 EBP 323/4885SIGMAR1 1897/4885KMT2A 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.